The company will continue to offer up to $700 reduction on each eligible patient’s initial out-of-pocket cost from their commercial insurer
Sun Pharma has announced the extension of its Imatinib Mesylate savings card programme. The company launched the programme as part of the Imatinib Mesylate launch in February 2016. The programme is aimed at delivering greater access to the drug by patients who have commercial insurance, but whose out-of-pocket cost may exceed an affordable amount.
As part of the Imatinib Mesylate savings card programme extension, Sun Pharma will continue to offer up to $700 reduction on each eligible patient’s initial out-of-pocket cost from their commercial insurer thereby reducing the patient’s out-of-pocket co-payment to as low as $10. This benefit will cover a patient’s monthly fills for a 30-day supply of Sun Pharma’s Imatinib Mesylate prescribed for Ph+CML, a form of chronic myeloid leukemia through the extension period.
During the first six months following its launch on February 1, more than 5,000 prescriptions for Sun Pharma’s Imatinib Mesylate have been filled by patients utilising this savings card program. The benefit to patients was in the range of a 50 per cent to 60 per cent reduction in out-of-pocket costs. Patients in the US who wish to utilise the programme can download the savings card by visiting Sun Pharma’s Imatinib Mesylate website at www.imatinibrx.com. The company will also continue its Hub service wherein patients can call and speak with a healthcare professional and discuss FDA approved uses for Imatinib Mesylate.
EP News Bureau – Mumbai